American Heart Association announcement validates the critical role of
self-care in the treatment of high blood pressure
NEW YORK, May 29 /PRNewswire/ -- InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced its support of the new joint scientific statement from the American Heart Association, American Society of Hypertension and the Preventive Cardiovascular Nurses' Association declaring that people with hypertension should routinely monitor their blood pressure at home to help manage the disease. This is the first statement issued by the American Heart Association detailing such recommendations for home blood pressure monitor use.
"We applaud the AHA, ASH and the Preventative Cardiovascular Nurses' Association for their joint decision to support widespread use of home blood pressure monitors," said Erez Gavish, president and CEO of InterCure. "This endorsement highlights the medical community's growing reliance on patient involvement to best manage serious health conditions. Much like diabetes care, an effective hypertension treatment plan requires patient empowerment, home-based monitoring and therapy options tailored to the patient. Home blood pressure monitoring provides motivating feedback for patients to stay compliant with their treatment regimens. But, patients must also be involved in determining the therapy options best suited for them -- including medications, lifestyle modifications or clinically-proven therapeutic device options, such as RESPeRATE."
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only
medical device on the market clinically proven to lower blood pressure
through paced breathing therapy. The device uses the body's natural
tendency to follow external rhythms, interactively guiding the user to
effortlessly reduce their breathing rate to a "therapeutic zone" of less
than 10 breaths per minute. The breathing exercises w
|SOURCE InterCure Ltd.|
Copyright©2008 PR Newswire.
All rights reserved